Table 1.
Characteristics of the included randomized controlled trials
| Trial | Indication | HES group | Control group | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Program | Patients (n) | Age | Weight (kg) | Program | Patients (n) | Age | Weight (kg) | ||
| Liet et al. 2006 [14] | Hypotensive neonates with low cardiac output and absence of myocardial dysfunction | 6%HES 200/0.5 | 7 | 5 ± 6d | 1.4 ± 0.7 | 5% Albumin Isotonic saline | 7 | 2 ± 1d | 1.3 ± 0.6 |
| 7 | 6 ± 10d | 0.9 ± 0.3 | |||||||
| Standl et al. 2008 [15] | Non-cardiac surgery | 6%HES 130/0.4 | 41 | 8.3 ± 9.2 m | 8.0 ± 6.6 | 5% Albumin | 40 | 8.7 ± 10.9 m | 7.1 ± 4.6 |
| Akech et al. 2010 [16] | Severe falciparum malaria | 6%HES 130/0.4 | 40 | 40.3 ± 12.8 m | - | 6% Dextran | 39 | 40.3 ± 12.8 m | - |
| Van Der Linden et al. 2013 [17] | Undergoing elective surgery for congenital heart disease | 6%HES 130/0.4 | 31 | 6.1 ± 5.2Y | 25.1 ± 24.6 | 5% Albumin | 29 | 4.8 ± 3.7y | 16.7 ± 10.3 |
| Liet et al. 2003 [18] | Plasma volume expansion with HES in the newborn | 6% HES 200/0.5 | 13 | 3 ± 2.2d | 1.27 ± 0.47 | 5% Albumin | 13 | 5 ± 3d | 1.33 ± 0.64 |
| Hanart et al. 2009 [19] | Undergoing cardiac surgery with cardiopulmonary bypass | 6%HES 130/0.4 | 60 | 23.5 ± 19.8 m | 9 ± 4 | 4% Albumin | 59 | 17.3 ± 20.0 m | 8 ± 4.3 |
| Akkucuk et al. 2013 [20] | Children undergoing cardiac surgery | 6%HES 130/0.4 | 12 | 3.9 ± 1.7y | 13.5 ± 4.5 | Ringer’s acetate | 12 | 5.1 ± 3.7y | 16.2 ± 8.8 |
| Chong Sung et al. 2006 [21] | Undergoing elective repair of atrial septal defect, ventricular septal defect or tetralogy of Fallo | 6%HES 130 ⁄0.4 | 21 | 31.5 ± 34.6 m | 13.7 ± 8.9 | Fresh frozen plasma | 21 | 43.5 ± 61.6 m | 15.7 ± 13.4 |
| Haas et al. 2007 [22] | Prevention of intra-operative hypovolemia | 6% HES 130 ⁄0.4 | 14 | 9 ± m | 9 ± 2 | 5% Albumin 4% Gelatine | 14 | 14 ± 9 m | 10 ± 2 |
| 14 | 10 ± 10 m | 8 ± 3 | |||||||
| Wills et al. 2005 [23] | Dengue shock syndrome | 6%HES 200/0.5 | 129 | 9.6 ± 4.9y | 26 ± 13.3 | 5% Dextran Ringer’s lactate | 126 | 10 ± 4.1y | 27 ± 14.5 |
| 128 | 9.8 ± 4.6y | 26.8 ± 13.9 | |||||||
| Wills et al. 2005 [23] | Dengue shock syndrome | 6%HES 200/0.5 | 62 | 9.3 ± 4.6y | 24.8 ± 14.1 | 5% Dextran | 67 | 8.8 ± 4.6y | 25.5 ± 13.4 |
| Sahoo et al. 2007 [24] | with CCHD undergoing modified BT shunt operations | 6%HES 200/0.5 | 25 | 17.7 ± 12.3 m | 7.0 ± 2.4 | 5% Dextran | 25 | 19.5 ± 14.3 m | 7.9 ± 2.4 |
| Osthaus et al. 2009 [25] | Aged 0 to 12 years scheduled for surgery | 6%HES 130/0.4 | 25 | 4.4 ± 6.4y | 18.7 ± 22.2 | 4% Gelatin | 25 | 4.6 ± 6.3y | 20.2 ± 25.0 |
| Witt et al. 2008 [26] | Major pediatric surgery | 6% HES | 25 | 33.2 ± 40 m | 13.4 ± 11 | 4%Gelatin | 25 | 38.7 ± 39 m | 14.2 ± 10 |
| 130/0.4 | |||||||||